We help psychiatrists identify the best treatment for patients with depression, including medications and other biomedical interventions. Before treatment begins, we analyze brain data from EEG and ECG and generate a medical report to support clinical decision making. Our focus is on treatment decisions that are currently driven by trial and error, improving outcomes by +24% while reducing treatment costs.
The solution is regulatory approved in Switzerland and recently in the UK and UAE. It is fully reimbursed and actively used in Switzerland. With EU approval expected in Q3 2026, and DeepPsy is ready to scale.